Phase I trial patients

In our phase I clinical trial, we highlight the capacity of Dex based-vaccines to restore the number and NKG2D-dependent function of NK cells in 7/14 cancer patients.

created over 15 years ago (17 December 2009)    last modified over 13 years ago (28 September 2011)   [ RDF ]   [ RelFinder ]